Evolent Health (NYSE:EVH) Price Target Lowered to $4.00 at Citigroup

Evolent Health (NYSE:EVH) had its price target lowered by research analysts at Citigroup from $6.00 to $4.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the technology company’s stock. Citigroup’s price objective points to a potential upside of 19.94% from the company’s previous close.

A number of other analysts have also weighed in on EVH. BMO Capital Markets reaffirmed an “outperform” rating and issued a $3.50 price objective on shares of Evolent Health in a research note on Wednesday. UBS Group reduced their price target on shares of Evolent Health from $10.00 to $5.00 and set a “buy” rating for the company in a report on Thursday. Royal Bank Of Canada cut their price objective on shares of Evolent Health from $5.00 to $3.00 and set a “sector perform” rating on the stock in a report on Wednesday. Citizens Jmp reduced their price target on Evolent Health from $11.00 to $10.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 6th. Finally, Needham & Company LLC decreased their price objective on Evolent Health from $15.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.50.

Evolent Health Trading Up 6.2%

Shares of NYSE:EVH traded up $0.20 on Thursday, hitting $3.34. 4,017,498 shares of the company’s stock were exchanged, compared to its average volume of 3,108,708. The business’s 50 day simple moving average is $3.52 and its two-hundred day simple moving average is $5.85. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.33 and a quick ratio of 1.33. The stock has a market capitalization of $372.19 million, a price-to-earnings ratio of -0.65 and a beta of 0.27. Evolent Health has a 12 month low of $2.50 and a 12 month high of $12.06.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Tuesday, February 24th. The technology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.30%. The company had revenue of $468.72 million during the quarter, compared to analysts’ expectations of $468.48 million. During the same period in the previous year, the company earned ($0.02) EPS. The firm’s quarterly revenue was down 27.5% on a year-over-year basis. Analysts anticipate that Evolent Health will post 0.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Evolent Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its stake in Evolent Health by 88.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock valued at $29,000 after purchasing an additional 1,194 shares during the last quarter. CIBC Private Wealth Group LLC lifted its holdings in shares of Evolent Health by 4,000.0% during the third quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock worth $35,000 after purchasing an additional 4,000 shares during the period. Strs Ohio acquired a new stake in shares of Evolent Health during the first quarter worth about $47,000. Vise Technologies Inc. purchased a new stake in Evolent Health in the fourth quarter valued at approximately $50,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in Evolent Health in the 3rd quarter worth approximately $51,000.

Key Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 results topped expectations — Evolent reported $0.08 EPS vs. $0.06 consensus and revenue of $468.7M (in line). The beat and the company’s commentary on execution are a near-term bullish trigger. Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results (PR Newswire)
• Positive Sentiment: Earnings call highlighted strong oncology growth and strategic wins — management pointed to market-share gains, strong renewal rates and continued migration to enhanced Performance Suite contracts, supporting medium-term revenue opportunities. Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Positive Sentiment: BTIG left a buy rating and set a new $8.00 target (down from $10) — still implies significant upside versus current levels and signals at least one institutional view that upside remains after the quarter. BTIG Research price target note
• Neutral Sentiment: FY2026 revenue guidance of $2.4B–$2.6B was provided and sits around consensus — the range keeps expectations steady but does not materially change the near-term story. FY2026 guidance in PR
• Neutral Sentiment: Headline coverage notes a sharp intraday move — media and retail attention (e.g., Yahoo Finance) likely amplified trading volume and the price bounce. That can produce short-term spikes without changing fundamentals. Evolent Health Shares Skyrocket (Yahoo Finance)
• Negative Sentiment: Royal Bank of Canada cut its target to $3.00 and moved to “sector perform” — this downgrade to a lower target adds selling pressure and signals more cautious institutional views. RBC price target note
• Negative Sentiment: Needham sharply cut its target from $15 to $4 while keeping a buy — the large reduction reduces the peg for upside and suggests lowered expectations for near-term recovery. Needham price target note
• Negative Sentiment: KeyCorp downgraded EVH from overweight to sector weight — another institutional shift toward caution that can weigh on sentiment and limit short-term rallies. Analyst downgrade coverage (TickerReport)

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.